You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
More than 70 percent of labs surveyed experienced supply chain interruptions, forcing them to validate three or more diagnostic testing methods.
The team anticipates launching its first clinical diagnostic assay, which will detect targeted, low-frequency genetic mutations in lung cancer, in 2021.
Cytek said the reagents consist of basic T, B, and NK cell cluster of differentiation markers used for lymphocyte subset detection.
Lexent's NGS assay for monitoring response to treatment and minimal residual disease for solid tumors will eventually run on the Illumina NextSeq 550Dx.
Aalto sells raw materials for in vitro diagnostics including purified human proteins, monoclonal and polyclonal antibodies, and viral antigens.
The blood grouping reagents for extended phenotype testing cover more than 99 percent of the most commonly tested blood-group antigens.
The assay can also be used to assess a broad range of metabolic conditions, including pancreatic tumors, liver disease, acromegaly, and others.
The arrangement will allow Illumina to market and promote Kailos' research solutions for pharmacogenetic target enrichment.
Kits with the affected products may not be able to fully extract nucleic acids from samples and detect infection or provide a correct diagnosis.
The dispute stems from a licensing agreement in 2005 covering reagent patents held by Abaxis. Cepheid filed a countersuit yesterday, claiming it has not breached the license and asking the court to declare Abaxis' patents invalid.